Discontinued — last reported Q4 '25
Additional Paid-In Capital
EquityEli Lilly Additional Paid-In Capital increased by 1.6% to $7.35B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 1.3%, from $7.44B to $7.35B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows relatively stable performance with a 1.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2008
Last reportedQ4 2025
How to read this metric
High growth in this account often reflects heavy reliance on stock-based compensation to attract and retain talent.
Detailed definition
The excess amount paid by investors over the par value of the shares issued. This often grows significantly in tech comp...
Peer comparison
High-growth tech companies typically show much larger APIC balances than traditional industrial firms.
Metric ID:
additional_paid_in_capitalHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.67B | $6.76B | $6.83B | $6.66B | $6.75B | $6.83B | $6.92B | $6.79B | $6.95B | $7.16B | $7.25B | $7.01B | $7.21B | $7.34B | $7.44B | $6.91B | $7.09B | $7.23B | $7.35B |
| QoQ Change | — | +1.3% | +1.1% | -2.6% | +1.3% | +1.2% | +1.4% | -1.9% | +2.3% | +3.0% | +1.3% | -3.3% | +2.9% | +1.7% | +1.4% | -7.1% | +2.6% | +2.0% | +1.6% |
| YoY Change | — | — | — | — | +1.2% | +1.1% | +1.3% | +2.1% | +3.0% | +4.8% | +4.8% | +3.2% | +3.8% | +2.5% | +2.6% | -1.4% | -1.7% | -1.5% | -1.3% |
Range$6.66B – $7.44B
CAGR+2.2%
Avg YoY Growth+1.6%
Median YoY Growth+2.1%
Current Streak3 quarters growth
Additional Paid-In Capital at Other Companies
Frequently Asked Questions
- What is Eli Lilly's additional paid-in capital?
- Eli Lilly (LLY) reported additional paid-in capital of $7.35B in Q4 2025.
- How has Eli Lilly's additional paid-in capital changed year-over-year?
- Eli Lilly's additional paid-in capital decreased by 1.3% year-over-year, from $7.44B to $7.35B.
- What is the long-term trend for Eli Lilly's additional paid-in capital?
- Over 5 years (2020 to 2025), Eli Lilly's additional paid-in capital has grown at a 1.6% compound annual growth rate (CAGR), from $6.78B to $7.35B.
- What does additional paid-in capital mean?
- The extra money investors paid for stock above its basic legal par value.